Bookmark and Share

Compound Summary for: CID 10274777

aleglitazar

Also known as: 475479-34-6; UNII-41T4OAG59U; Aleglitazar (USAN); RO-0728804; R-1439; CHEMBL519504; CHEBI:620672; DB08483; RO 0728804
Molecular Formula: C24H23NO5S   Molecular Weight: 437.50812   InChIKey: DAYKLWSKQJBGCS-NRFANRHFSA-N
Aleglitazar is an investigational drug from the company Hoffmann??La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes. In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects and toxicity.   From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Literature
Patents
Biomolecular Interactions and Pathways
Biological Test Results
Classification
Chemical and Physical Properties
_ _